{
    "clinical_study": {
        "@rank": "115997", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "biospec_descr": {
            "textblock": "Blood Samples"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "In this single center study blood samples for biomarker analysis will be collected from\n      patients with spinal muscular atrophy. Up to 21 mL blood will be drawn from eligible\n      patients at a single visit."
        }, 
        "brief_title": "A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Muscular Atrophy, Spinal", 
        "condition_browse": {
            "mesh_term": [
                "Muscular Atrophy", 
                "Muscular Atrophy, Spinal", 
                "Atrophy"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Self-identified as 5q-autosomal recessive spinal muscular atrophy (SMA) type I, II or\n             III as judged by their neurologist upon diagnosis\n\n          -  Ability and willingness to provide blood samples\n\n          -  Willingness (by the patient or patient's parents or legal guardian) to complete to\n             their best ability a questionnaire which requests specific clinical and genetic\n             information\n\n          -  Able to participate and willing to give written informed consent or assent. Informed\n             consent will be obtained from the patient, or the patient's parent or legal guardian.\n\n        Exclusion Criteria:\n\n          -  Any known genetic condition other than spinal muscular atrophy, unless it is not\n             interfering with the purpose of this study based on the Sponsor's judgment\n\n          -  Participation in a clinical trial (except observational studies) within the previous\n             14 days\n\n          -  Donation of blood or significant blood loss within three months prior to screening\n\n          -  Concomitant disease or condition that could interfere with, or treatment of which\n             might interfere with, the conduct of this study, or that would, in the opinion of the\n             investigator, pose an unacceptable risk to the patient in this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with spinal muscular atrophy"
            }
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01910168", 
            "org_study_id": "BE29002"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kalamazoo", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49007"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84132"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Single Center Study to Collect Samples From SMA Patients for Biomarker Analysis", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "SMN1/SMN2 detection in blood by mRNA assay", 
            "safety_issue": "No", 
            "time_frame": "1 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01910168"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "SMN protein level in blood/lymphocytes", 
            "safety_issue": "No", 
            "time_frame": "1 day"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "collaborator": {
                "agency": "PTC Therapeutics", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}